Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04570956
Other study ID # CA237607
Secondary ID NCI-2022-029735R
Status Recruiting
Phase Phase 2
First received
Last updated
Start date July 26, 2021
Est. completion date December 31, 2026

Study information

Verified date June 2024
Source Mayo Clinic
Contact Denice Gehling, RN
Phone 507-538-1628
Email gehling.denice@mayo.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators plan to prospectively study breast tissue changes after a short course of Tamoxifen (Tam).


Description:

Women with atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS) are at increased risk of breast cancer (BC) (~1-2 % per year). Over two decades ago, placebo-controlled randomized trials established that oral tamoxifen (20 mg/day) reduces breast cancer risk by 50% in generally defined high risk women, with ~70% reduction in women at high risk specifically due to atypical hyperplasia.[1] Years later, the side effects and toxicity of oral tamoxifen at 20 mg/day remain a significant barrier to its uptake and longterm compliance.[2, 3] To address the issue of toxicity, two main strategies have been pursued: 1) using a lower dose of oral tamoxifen, and 2) using a topical formulation of tamoxifen to avoid systemic side effects. The investigators will perform a prospective study of women with AH or LCIS who will take a short course of prevention therapy; breast tissue samples will be evaluated pre- and post-therapy to identify and evaluate very early biomarkers of response. The overall goal of the study is to evaluate short-term changes in background breast tissue induced by either low-dose oral tamoxifen or topical 4-OHT gel in women with AH or LCIS.


Recruitment information / eligibility

Status Recruiting
Enrollment 104
Est. completion date December 31, 2026
Est. primary completion date December 31, 2026
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Willing to return to enrolling institution for follow-up - Willing to complete required testing - Ability to complete questionnaire by themselves or with assistance - Female (sex that was assigned at birth) - Ipsilateral intact breast with histology confirmation of atypical ductal or lobular hyperplasia, or lobular carcinoma in situ (LCIS), within the last 12 months, whether surgically excised or not.; OR neither AH nor LCIS but increased breast cancer risk defined as either: - Gail model (Breast Cancer Risk Assessment Tool) 5 year breast cancer risk of >= 3%, or - International Breast Intervention Study model 10 year breast cancer risk of >= 5%. - Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%) - The effects of topical afimoxifene (4-OHT) gel on the developing human fetus at the recommended therapeutic dose are unknown. However, oral tamoxifen is Pregnancy Category D-positive evidence of human fetal risk. For this reason, and because triphenylethylene antiestrogens, including tamoxifen, are known to be teratogenic, women of childbearing potential and their male partners must agree to use at least one effective form of birth control (abstinence is not an allowed method) prior to study entry and for the duration of study participation, and for 2 months following the last dose of study medications (participant can resume oral birth control pills for effective birth control measures after post-treatment biopsy is done). Effective birth control methods during treatment are: copper and Mirena intrauterine device (IUD), diaphragm/cervical cap/shield, spermicide, contraceptive sponge, condoms. Tubal Ligation is an acceptable method of birth control. Women of childbearing potential must have a negative pregnancy test within five days before starting study medications. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately. - Willingness to avoid exposing breast skin to natural or artificial sunlight (i.e. tanning beds) for the duration of the study. - Participants must have acceptable organ and marrow function as judged by treating physician's evaluation of baseline laboratory data. - Negative pregnancy (serum or urine) test if of childbearing potential and/or follicle stimulating hormone (FSH) to verify menopausal status. Exclusion Criteria: - Clinically suspicious mass/lesions - Breast cancer in the past 5 years. - Patients with any history of venous thromboembolic disease, regardless of timeframe (history of varicose veins and superficial phlebitis is allowed). - Current pregnancy or lactation. - History of other prior breast cancer-specific therapy within the previous 2 years (chemotherapy, anti-HER2 agents, endocrine agents, everolimus, CDK4-6 inhibitors). - Cytotoxic chemotherapy for any indication in last 2 years. - Prior use of selective estrogen receptor modulator (SERMS) or AIs including tamoxifen, raloxifene, anastrozole, letrozole, or exemestane for prevention or therapy within the past 5 years unless: - Use was less than 6 months duration in the past 5 years and not used in the 1 year prior to enrollment, or - Use was no greater than 2 months duration in the past 1 year and not used in the 6 months prior to enrollment. - Exogenous sex steroid, including oral contraceptive pill use within 1 month prior to pretreatment breast biopsy. Use of vaginally administered estrogens and hormone coated IUD such as Mirena is permitted. - History of any prior ipsilateral breast radiotherapy. Previous unilateral radiation of the contralateral side is allowed. - Skin lesions on the breast that disrupt the stratum corneum (e.g., eczema, ulceration). - History of endometrial neoplasia - Current smoker. Cessation for at least 6 weeks - Current users of potent inhibitors of tamoxifen metabolism. The potent inhibitors of tamoxifen metabolism are: bupropion, cinacalcet, fluoxetine, paroxetine, quinidine. - Participants may not be receiving any other investigational agents within 90 days of enrollment or during this study. - History of allergic reactions to tamoxifen. - Uncontrolled intercurrent illness that in the judgement of the treating physician would make them unsuitable for study participation - Current use of anticoagulation medications. - Patients who are breastfeeding. - Hemoglobin < 10 g/dL (within 30 days of randomization). - Leukocytes < 3,000/microliter (within 30 days of randomization). - Platelets < 100,000/microliter (within 30 days of randomization). - Total bilirubin > 1.5 x institutional upper limit of normal (ULN) (within 30 days of randomization). - Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT) > 1.5 x ULN (within 30 days of randomization). - Alanine aminotransferase (ALT) serum glutamate pyruvate transaminase (SGPT) > 1.5 x ULN (within 30 days of randomization). - Alkaline phosphatase, S > 1.5 x ULN (within 30 days of randomization). - Albumin, S > 1.5 x ULN (within 30 days of randomization). - Protein, total, S > 1.5 x ULN (within 30 days of randomization). - Creatinine > 1.5 x ULN (within 30 days of randomization). - Antithrombin III <80% of normal. - Fibrinogen >1000 mg/dL. - Patients who are taking any medications, herbal products, or over the counter (OTC) products that are moderate or strong CYP2D6 inhibitors or CYP3A inducers. Patients should also refrain from starting any drug or product with these properties during the study. This is to avoid any potential interactions with tamoxifen or 4-OHT. - Clinically significant arrhythmia requiring ongoing medication for control / treatment, especially those with high risk of QT prolonging effects. - Identification of a clinically suspicious mass on examination.

Study Design


Intervention

Drug:
Tamoxifen
Oral Tamoxifen 10 mg/day
Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day
Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day
Placebo
placebo pill or placebo gel
Other:
Questionnaire Administration
Ancillary studies

Locations

Country Name City State
United States Northwestern University Evanston Illinois
United States Mayo Clinic Rochester Minnesota

Sponsors (2)

Lead Sponsor Collaborator
Amy C. Degnim National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The purpose of this research is to evaluate short-term changes in background breast tissue induced by oral tamoxifen or 4-OHT gel in women with atypical hyperplasia or lobular carcinoma in situ (LCIS). Treatment Evaluation/Measurement of Effect 48 months
See also
  Status Clinical Trial Phase
Recruiting NCT04996316 - MammoScreen Breast Cancer Risk Assessment and Decision Aid for Breast Cancer Screening and Referrals
Enrolling by invitation NCT05558917 - Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery N/A
Completed NCT05526872 - A Patient Reminder and Self-Referral Via Online Patient Portals and Text Messaging to Improve Adherence to Breast Cancer Screening N/A
Not yet recruiting NCT05178498 - Impact of Dietary Inflammatory Potential on Breast Cancer Risk
Recruiting NCT05544123 - The Treatment Situation of Chinese County Population With Breast Cancer
Withdrawn NCT05191004 - Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC Phase 1/Phase 2
Terminated NCT02890368 - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides Phase 1
Recruiting NCT01462903 - A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors Phase 1
Completed NCT01422408 - Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy Phase 2
Terminated NCT00770354 - Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer Phase 2
Terminated NCT02810873 - Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer N/A
Withdrawn NCT03185871 - Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses Phase 2
Completed NCT02983279 - Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer N/A
Active, not recruiting NCT02194387 - Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members N/A
Recruiting NCT05406232 - Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
Recruiting NCT03408353 - Mammography, Early Detection Biomarkers, Risk Assessment, and Imaging Technologies, MERIT Study
Completed NCT01641068 - Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms N/A
Withdrawn NCT04190433 - Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial Phase 2
Recruiting NCT04799535 - Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
Terminated NCT02923037 - Hatha Yoga in Breast Cancer Survivors N/A

External Links